Mechanisms of Protein Misfolding in Conformational Lung Diseases

被引:0
|
作者
McElvaney, N. G. [1 ]
Greene, C. M. [1 ]
机构
[1] Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Resp Res Div,Dept Med, Dublin 9, Ireland
基金
爱尔兰科学基金会;
关键词
Alpha-1; antitrypsin; cigarette smoke; cystic fibrosis transmembrane conductance regulator; endoplasmic reticulum stress; TRANSMEMBRANE CONDUCTANCE REGULATOR; MUTANT ALPHA-1-ANTITRYPSIN Z; MEDIATE INCREASED SECRETION; NUCLEOTIDE-BINDING DOMAIN; CYSTIC-FIBROSIS LUNG; Z ALPHA(1)-ANTITRYPSIN; ENDOPLASMIC-RETICULUM; NEUTROPHIL ELASTASE; CIGARETTE-SMOKE; SERPIN POLYMERIZATION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Genetic or environmentally-induced alterations in protein structure interfere with the correct folding, assembly and trafficking of proteins. In the lung the expression of misfolded proteins can induce a variety of pathogenetic effects. Cystic fibrosis (CF) and alpha-1 antitrypsin (AAT) deficiency are two major clinically relevant pulmonary disorders associated with protein misfolding. Both are genetic diseases the primary causes of which are expression of mutant alleles of the cystic fibrosis transmembrane conductance regulator (CFTR) and SERPINA1, respectively. The most common and best studied mutant forms of CFTR and AAT are Delta F508 CFTR and the Glu342Lys mutant of AAT called ZAAT, respectively. Non-genetic mechanisms can also damage protein structure and induce protein misfolding in the lung. Cigarette-smoke contains oxidants and other factors that can modify a protein's structure, and is one of the most significant environmental causes of protein damage within the lung. Herein we describe the mechanisms controlling the folding of wild type and mutant versions of CFTR and AAT proteins, and explore the consequences of cigarette-smoke-induced effects on the protein folding machinery in the lung.
引用
收藏
页码:850 / 859
页数:10
相关论文
共 50 条
  • [41] Roles of molecular chaperones in protein misfolding diseases
    Barral, JM
    Broadley, SA
    Schaffar, G
    Hartl, FU
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2004, 15 (01) : 17 - 29
  • [42] Protein misfolding diseases: Prospects of pharmacological treatment
    Gamez, A.
    Yuste-Checa, P.
    Brasil, S.
    Briso-Montiano, A.
    Desviat, L. R.
    Ugarte, M.
    Perez-Cerda, C.
    Perez, B.
    CLINICAL GENETICS, 2018, 93 (03) : 450 - 458
  • [43] The role of protein misfolding in the pathogenesis of human diseases
    Ellisdon, AM
    Bottomley, SP
    IUBMB LIFE, 2004, 56 (03) : 119 - 123
  • [44] Cell death: protein misfolding and neurodegenerative diseases
    Nakamura, Tomohiro
    Lipton, Stuart A.
    APOPTOSIS, 2009, 14 (04) : 455 - 468
  • [45] Mechanisms of and therapeutic strategies against misfolding diseases.
    Kelly, JW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U720 - U720
  • [46] Recent developments in targeting protein misfolding diseases
    Denny, Rajiah Aldrin
    Gavrin, Lori Krim
    Saiah, Eddine
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (07) : 1935 - 1944
  • [47] The role of neuroprotective chaperones in protein misfolding diseases
    Donnelier, Julien
    Braun, Janice
    PRION, 2015, 9 : S85 - S86
  • [48] Cell death: protein misfolding and neurodegenerative diseases
    Tomohiro Nakamura
    Stuart A. Lipton
    Apoptosis, 2009, 14 : 455 - 468
  • [49] Cellular stress responses in protein misfolding diseases
    Duennwald, Martin L.
    FUTURE SCIENCE OA, 2015, 1 (02):
  • [50] Therapeutic approaches to protein-misfolding diseases
    Cohen, FE
    Kelly, JW
    NATURE, 2003, 426 (6968) : 905 - 909